uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Infectious Diseases.
2013 (English)In: Infection Ecology & Epidemiology, ISSN 2000-8686, Vol. 3, 20766- p.Article in journal (Refereed) Published
Abstract [en]


In Sweden in 2009, two doses of the pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine were recommended for those with HIV infection along with one dose of seasonal trivalent influenza vaccine (TIV). At that time, no data for HIV patients and their response to the adjuvanted vaccine were available.


Forty-two HIV-infected individuals were vaccinated with the pandemic vaccine on study days 0 and 28. Twenty-one of them received TIV on day 56 and 21 did not. Serum samples were taken at these time points, and also on day 86 and after 1 year for serologic analyses.


Before vaccination, none of the 42 patients had putatively protective levels of antibodies (haemagglutination inhibition [HI] titres ≥1:40) to the pandemic-like strain A/California/7/2009 H1N1. After dose 1, the seroprotection rate (SPR) and seroconversion rate (SCR) were both 69% (29 of 42). After dose 2, the SPR and SCR were 89 and 86%, respectively. At 1 year, 10 (34%) of 29 had protective antibodies and 16 (62%) of 26 who had had protective antibody levels had lost them. There was a retained factor increase of the geometric mean titre (GMT) of 3.9. Serological analyses could be performed in 19 subjects who were vaccinated with TIV and in 21 who were not. Protective antibodies to the three strains before vaccination were 20-37%. The SCR was 26% to A/Brisbane/59/2007 H1N1, 47% to A/Uruguay/10/2007/ H3N2 and 42% to B/Brisbane/60/2008. At 1 year, the factor increase of GMT was 1.8 to the two influenza A strains.


Two doses of adjuvanted influenza vaccine improved the SCR and the SPR among HIV-infected subjects. Long-term follow-up indicates revaccination in the next influenza season whether they received an adjuvanted or non-adjuvanted influenza vaccine.

Place, publisher, year, edition, pages
2013. Vol. 3, 20766- p.
Keyword [en]
Adults, Pneumococcal conjugate vaccine, PCV13
National Category
Infectious Medicine
URN: urn:nbn:se:uu:diva-224042DOI: 10.3402/iee.v3i0.20766PubMedID: 24003363OAI: oai:DiVA.org:uu-224042DiVA: diva2:714965
Available from: 2014-04-30 Created: 2014-04-30 Last updated: 2014-06-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Pauksens, Karlis
By organisation
Infectious Diseases
In the same journal
Infection Ecology & Epidemiology
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 103 hits
ReferencesLink to record
Permanent link

Direct link